Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

NCT03459079 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03459079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03459079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2018
Completion date
June 1, 2023
Enrollment
128 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver disease (nafld), type 2 diabetes (t2dm)